Paraoxonase-1 activity and oxidative stress in patients with anterior ST elevation myocardial infarction undergoing primary percutaneous coronary intervention with and without no-reflow

Atherosclerosis

Volumn 234, Issue 2, 2014, Pages 415-420

  Gür, Mustafa ^a   Türkoǧlu, Caner ^a   Taşkin, Abdullah ^b   Uçar, Hakan ^a   Börekçi, Abdurrezzak ^c   Şeker, Taner ^a   Gözükara, Mehmet Yavuz ^d   Kaypakli, Onur ^a   Akyol, Selahattin ^a   Selek, Şahbettin ^b   Şahin, Durmuş Yildiray ^a   Elbasan, Zafer ^a   Çayli, Murat ^a  

^a Adana Numune Training and Research Hospital   (Turkey)

^b HARRAN UNIVERSITY   (Turkey)

^c KAFKAS UNIVERSITY   (Turkey)

^d MERSIN STATE HOSPITAL   (Turkey)

Author keywords

Antioxidant; Myocardial infarction; No reflow; Oxidative stress; Paraoxonase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; BIOLOGICAL MARKER; LIPID HYDROPEROXIDE; ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; LIPID PEROXIDE; OXIDIZING AGENT; PON1 PROTEIN, HUMAN;

ADULT; ANGIOCARDIOGRAPHY; AREA UNDER THE CURVE; ARTICLE; AUTOMATION; DIABETES MELLITUS; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NO REFLOW PHENOMENON; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SPECTROPHOTOMETRY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SYNTAX SCORE; AGED; ANTERIOR WALL MYOCARDIAL INFARCTION; BLOOD; ENZYMOLOGY; METABOLISM; MIDDLE AGED; NO-REFLOW PHENOMENON; RISK FACTOR; TREATMENT OUTCOME;

ADULT; AGED; ANTERIOR WALL MYOCARDIAL INFARCTION; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; FEMALE; HUMANS; LIPID PEROXIDES; MALE; MIDDLE AGED; NO-REFLOW PHENOMENON; OXIDANTS; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84900836935     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.03.005     Document Type: Article

References (31)

1. Kloner R.A. No-reflow phenomenon: maintaining vascular integrity. JCardiovasc Pharmacol Ther 2011, 16:244-250.
2. Ndrepepa G., Tiroch K., Fusaro M., Keta D., Seyfarth M., Byrne R.A., et al. 5-Year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. JAm Coll Cardiol 2010, 55:2383-2389.
3. Niccoli G., Burzotta F., Galiuto L., Crea F. Myocardial no-reflow in humans. JAm Coll Cardiol 2009, 54:281-292.
4. Fearon I.M., Faux S.P. Oxidative stress and cardiovascular disease: novel tools give (free) radical insight. JMol Cell Cardiol 2009, 47:372-381.
5. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. JClin Invest 1998, 101:1581-1590.
6. Schiller N.B., Shah P.M., Crawford M., Demaria A., Devreux R., Feigenbaum H., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. JAm Soc Echocardiogr 1989, 2:358-367.
7. Gibson C.M., de Lemos J.A., Murphy S.A., Marble S.J., McCabe C.H., Cannon C.P., et al. TIMI Study Group, Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation 2001, 103:2550-2554.
8. Sianos G., Morel M.A., Kappetein A.P., Morice M.C., Colombo A., Dawkins K., et al. The SYNTAX score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005, 1:219-227.
9. Eckerson H.W., Wyte C.M., La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983, 35:1126-1138.
10. Arab K., Steghens J.P. Plasma lipid hydroperoxides measurement by an automated xylenol orange method. Anal Biochem 2004, 325:158-163.
11. Erel O. Anovel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem 2004, 37:112-119.
12. Erel O. Anew automated colorimetric method for measuring total oxidant status. Clin Biochem 2005, 38:1103-1111.
13. Şahin D.Y., Gür M., Elbasan Z., Kuloǧlu O., Şeker T., Kivrak A., et al. SYNTAX score is a predictor of angiographic no-reflow in patients with ST-elevation myocardial infarction treated with a primary percutaneous coronary intervention. Coron Artery Dis 2013, 24:148-153.
14. Nedeljkovic Z.S., Gokce N., Loscalzo J. Mechanisms of oxidative stress and vascular dysfunction. Postgrad Med J 2003, 79:195-199.
15. Guerin P., Bigot E., Patrice T. Evidence for antioxidants consumption in the coronary blood of patients with an acute myocardial infarction. JThromb Thrombolysis 2013, 35:41-47.
16. Perrelli M.G., Pagliaro P., Penna C. Ischemia/reperfusion injury and cardioprotective mechanisms: role of mitochondria and reactive oxygen species. World J Cardiol 2011, 3:186-200.
17. Becker L.B. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res 2004, 61:461-470.
18. Ovize M., Baxter G.F., Di Lisa F., Ferdinandy P., Garcia-Dorado D., Hausenloy D.J., et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res 2010, 87:406-423.
19. Harling L., Rasoli S., Vecht J.A., Ashrafian H., Kourliouros A., Athanasiou T. Do antioxidant vitamins have an anti-arrhythmic effect following cardiac surgery? A meta-analysis of randomised controlled trials. Heart 2011, 97:1636-1642.
20. Reffelmann T., Kloner R.A. The no-reflow phenomenon: a basic mechanism of myocardial ischemia and reperfusion. Basic Res Cardiol 2006, 101:359-372.
21. Bhattacharyya T., Nicholls S.J., Topol E.J., Zhang R., Yang X., Schmitt D., et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008, 299:1265-1276.
22. Akçay A.B., Camsari A., Ozcan T., Ciçek D., Akkuş N., Seyis S., et al. The relationship between paraoxonase-1 activity and coronary artery disease in patients with metabolic syndrome. Turk Kardiyol Dern Ars 2011, 39(5):371-377.
23. Kopetz V.A., Penno M.A., Hoffmann P., Wilson D.P., Beltrame J.F. Potential mechanisms of the acute coronary syndrome presentation in patients with the coronary slow flow phenomenon - insight from a plasma proteomic approach. Int J Cardiol 2012 Apr 5, 156(1):84-91.
24. Limbruno U., De Carlo M., Pistolesi S., Micheli A., Petronio A.S., Camacci T., et al. Distal embolization during primary angioplasty: histopathologic features and predictability. Am Heart J 2005, 150:102-108.
25. Molyneux C.A., Glyn M.C., Ward B.J. Oxidative stress and cardiac microvascular structure in ischemia and reperfusion: the protective effect of antioxidant vitamins. Microvasc Res 2002, 64:265-277.
26. Ndrepepa G., Tiroch K., Keta D., Fusaro M., Seyfarth M., Pache J., et al. Predictive factors and impact of no reflow after primary percutaneous coronary intervention in patients with acute myocardial infarction. Circ Cardiovasc Interv 2010 Feb 1, 3(1):27-33.
27. Skyschally A., Leineweber K., Gres P., Haude M., Erbel R., Heusch G. Coronary microembolization. Basic Res Cardiol 2006, 101:373-382.
28. Sen N., Afsar B., Ozcan F., Buyukkaya E., Isleyen A., Akcay A.B., et al. The neutrophil to lymphocyte ratio was associated with impaired myocardial perfusion and long term adverse outcome in patients with ST-elevated myocardial infarction undergoing primary coronary intervention. Atherosclerosis 2013, 228:203-210.
29. Matsumoto H., Inoue N., Takaoka H., Hata K., Shinke T., Yoshikawa R., et al. Depletion of antioxidants is associated with no-reflow phenomenon in acute myocardial infarction. Clin Cardiol 2004, 27:466-470.
30. Rimm E.B., Stampfer M.J., Ascherio A., Giovannucci E., Colditz G.A., Willett W.C. Vitamin E consumption and the risk of coronary heart disease in men. NEngl J Med 1993, 328:1450-1456.
31. Stephens N.G., Parsons A., Schofield P.M., Kelly F., Cheeseman K., Mitchinson M.J. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996, 347:781-786.